News | June 08, 2009

Percutaneous Value Replacement is an Option for Elderly Who May Not Survive Open-Heart Surgery

June 8, 2009 - Patients unable to undergo open-heart surgery may be candidates for a new nonsurgical aortic valve replacement procedure, according to a study presented at the 20th Annual Scientific Sessions of the American Society of Echocardiography (ASE) being held this week in Washington, D.C..

Transcatheter aortic valve replacement is a promising new treatment for patients with severe aortic stenosis who are considered high-risk for conventional surgical aortic valve replacement. With this approach, echocardiography, or heart ultrasound, is used to guide interventional cardiologists through the procedure and to assess the effects of intervention after the procedure. While this study showed promising results, the FDA has not yet approved transcatheter procedures for aortic valve replacement.

“Some people with severe aortic stenosis, or narrowing of the aortic valve, are not good candidates for open-heart surgery, because they may have other medical conditions that would classify them as high risk for surgery,” said Dr. Linda D. Gillam of the Columbia University Medical Center in New York, a lead author on the study. “This less invasive approach proved to be as effective as surgical aortic valve replacement with the patients in the study and can be done in a cath lab with less stress to the patient and a shorter recovery period.”

A total of 24 patients with symptomatic aortic stenosis underwent successful transcatheter aortic valve replacement or surgical aortic valve replacement during the study. There were no significant baseline differences between the two approaches. The study concluded that transcatheter and surgical aortic valve replacement result in comparable improvements in radial strain, strain rate and left ventricular ejection fraction in elderly patients with severe symptomatic aortic stenosis.

“People in their 80s have a 5-10 percent mortality rate when undergoing surgery for aortic valve replacement,” Gillam said. “These findings are especially critical for elderly patients who could not survive open-heart surgery.”

The study was conducted by Kotaro Arai, Eiichi Hyodo, Rebecca T. Hahn, Weihong Li, Kohei Fujimoto, Roy Pizzarello, Susheel Kodali, Mathew Williams, Martin B. Leon, Shunichi Homma, and Linda D. Gillam at Columbia University Medical Center in New York, NY.

The American Society of Echocardiography (ASE) is a professional organization of physicians, cardiac sonographers, nurses and scientists involved in echocardiography, the use of ultrasound to image the heart and cardiovascular system.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now